Celltrion Inc (068270) - Total Assets
Based on the latest financial reports, Celltrion Inc (068270) holds total assets worth ₩23.16 Trillion KRW (≈ $15.69 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 068270 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Celltrion Inc - Total Assets Trend (2007–2025)
This chart illustrates how Celltrion Inc's total assets have evolved over time, based on quarterly financial data. See Celltrion Inc (068270) shareholders funds for net asset value and shareholders' equity analysis.
Celltrion Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Celltrion Inc's total assets of ₩23.16 Trillion consist of 27.8% current assets and 72.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.0% |
| Accounts Receivable | ₩1.79 Trillion | 8.0% |
| Inventory | ₩2.80 Trillion | 12.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.90 Trillion | 8.5% |
| Goodwill | ₩11.88 Trillion | 53.2% |
Asset Composition Trend (2007–2025)
This chart illustrates how Celltrion Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 068270 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celltrion Inc's current assets represent 27.8% of total assets in 2025, a decrease from 50.3% in 2007.
- Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, up from 2.6% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 61.0% of total assets, an increase from 1.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 53.2% of total assets.
Celltrion Inc Competitors by Total Assets
Key competitors of Celltrion Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
Germany | €249.51 Million |
|
Medincell SA
PA:MEDCL
|
France | €74.58 Million |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
USA | $104.69 Million |
Celltrion Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 1.60 | 2.77 |
| Quick Ratio | 0.80 | 0.77 | 2.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩1.88 Trillion | ₩2.06 Trillion | ₩1.70 Trillion |
Celltrion Inc - Advanced Valuation Insights
This section examines the relationship between Celltrion Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.16 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 6.1% |
| Total Assets | ₩22.33 Trillion |
| Market Capitalization | $26.76 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Celltrion Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Celltrion Inc's assets grew by 6.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Celltrion Inc (2007–2025)
The table below shows the annual total assets of Celltrion Inc from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩22.33 Trillion ≈ $15.14 Billion |
+6.08% |
| 2024-12-31 | ₩21.06 Trillion ≈ $14.27 Billion |
+5.71% |
| 2023-12-31 | ₩19.92 Trillion ≈ $13.50 Billion |
+238.06% |
| 2022-12-31 | ₩5.89 Trillion ≈ $3.99 Billion |
+3.83% |
| 2021-12-31 | ₩5.67 Trillion ≈ $3.85 Billion |
+13.03% |
| 2020-12-31 | ₩5.02 Trillion ≈ $3.40 Billion |
+30.07% |
| 2019-12-31 | ₩3.86 Trillion ≈ $2.62 Billion |
+10.18% |
| 2018-12-31 | ₩3.50 Trillion ≈ $2.37 Billion |
+6.35% |
| 2017-12-31 | ₩3.29 Trillion ≈ $2.23 Billion |
+9.01% |
| 2016-12-31 | ₩3.02 Trillion ≈ $2.05 Billion |
+9.96% |
| 2015-12-31 | ₩2.75 Trillion ≈ $1.86 Billion |
+18.34% |
| 2014-12-31 | ₩2.32 Trillion ≈ $1.57 Billion |
+17.38% |
| 2013-12-31 | ₩1.98 Trillion ≈ $1.34 Billion |
+14.17% |
| 2012-12-31 | ₩1.73 Trillion ≈ $1.17 Billion |
+23.14% |
| 2011-12-31 | ₩1.41 Trillion ≈ $953.72 Million |
+21.80% |
| 2010-12-31 | ₩1.16 Trillion ≈ $783.04 Million |
+106.63% |
| 2009-12-31 | ₩559.20 Billion ≈ $378.96 Million |
+12.01% |
| 2008-12-31 | ₩499.26 Billion ≈ $338.34 Million |
+712.34% |
| 2007-12-31 | ₩61.46 Billion ≈ $41.65 Million |
-- |
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for … Read more